Free Trial
NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

X4 Pharmaceuticals logo
$1.68 +0.01 (+0.60%)
As of 01:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About X4 Pharmaceuticals Stock (NASDAQ:XFOR)

Key Stats

Today's Range
$1.69
$1.79
50-Day Range
$1.67
$4.31
52-Week Range
$1.64
$26.96
Volume
366,397 shs
Average Volume
137,440 shs
Market Capitalization
$9.70 million
P/E Ratio
0.78
Dividend Yield
N/A
Price Target
$72.33
Consensus Rating
Buy

Company Overview

X4 Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

XFOR MarketRank™: 

X4 Pharmaceuticals scored higher than 93% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    X4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    X4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about X4 Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.68) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of X4 Pharmaceuticals is 0.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of X4 Pharmaceuticals is 0.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.07.

  • Price to Book Value per Share Ratio

    X4 Pharmaceuticals has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about X4 Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.63% of the float of X4 Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in X4 Pharmaceuticals has recently increased by 22.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    X4 Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    X4 Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.63% of the float of X4 Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in X4 Pharmaceuticals has recently increased by 22.15%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for X4 Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    Only 4 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, X4 Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,559.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 2.15% of the stock of X4 Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about X4 Pharmaceuticals' insider trading history.
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Stock News Headlines

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
See More Headlines

XFOR Stock Analysis - Frequently Asked Questions

X4 Pharmaceuticals' stock was trading at $22.0080 at the beginning of 2025. Since then, XFOR stock has decreased by 92.3% and is now trading at $1.70.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its earnings results on Thursday, May, 1st. The company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of ($4.13) by $4.17. The firm had revenue of $28.81 million for the quarter, compared to analyst estimates of $7.03 million. X4 Pharmaceuticals had a net margin of 46.54% and a negative trailing twelve-month return on equity of 181.56%.
Read the conference call transcript
.

X4 Pharmaceuticals shares reverse split on Monday, April 28th 2025.The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Intel (INTC).

Company Calendar

Last Earnings
5/01/2025
Today
7/09/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XFOR
CIK
1501697
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$120.00
Low Price Target
$7.00
Potential Upside/Downside
+4,154.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
0.81
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.45 million
Pretax Margin
47.58%

Debt

Sales & Book Value

Annual Sales
$2.56 million
Price / Cash Flow
N/A
Book Value
$3.90 per share
Price / Book
0.44

Miscellaneous

Free Float
5,665,000
Market Cap
$9.84 million
Optionable
Optionable
Beta
0.54
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:XFOR) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners